title: Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.
abstract: Lower urinary tract (LUT) smooth muscle can be relaxed by drugs that increase intracellular concentrations of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Both of these substances are degraded by phosphodiesterases (PDEs), which play a central role in the regulation of smooth muscle tone. The distribution and functional significance of PDE enzymes vary in different tissues of the LUT. Targeting specific PDE isoenzymes should thus allow organ selectivity. PDE 4 and 5 appear to predominate in the prostate, PDE 1 and 4 are thought to influence detrusor smooth muscle function, and PDE 5 may be functionally important in the urethra and vasculature. Studies on the use of PDE inhibitors to treat various LUT symptoms (LUTS), have yielded favorable results. Thus, positive effects of the PDE 5 inhibitors sildenafil and tadalafil on symptoms and quality of life in men with LUTS, erectile dysfunction, and BPH have also been demonstrated. These effects may be due to effects on cGMP signaling and/or modification of afferent input from bladder, urethral, and prostate tissue. This review gives an update on the distribution of PDEs in structures relevant for LUT function, and discusses how inhibition of these enzymes can contribute to beneficial effects on LUTS. Information for the review was obtained from searches of the PubMed database, and from the authors' files.
authors.affiliation: Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA. Karl-Eric.Andersson@med.lu.se
authors.forename: Karl-Erik
authors.initials: KE
authors.lastname: Andersson
authors.forename: Stefan
authors.initials: S
authors.lastname: Uckert
authors.forename: Christian
authors.initials: C
authors.lastname: Stief
authors.forename: Petter
authors.initials: P
authors.lastname: Hedlund
mesh_terms: D000818:Animals; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D011467:Prostate / Q000201:enzymology; D011470:Prostatic Hyperplasia / Q000150:complications*; D001743:Urinary Bladder / Q000201:enzymology; D053202:Urinary Incontinence, Urge / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*